GlycoBAR

GlycoBAR is a biotech which owns a biofermentation technology allowing to produce blood group antigen ligands at a cost that is - for the first time ever - compatible with the market. Thanks to these molecules, It becomes possible to make "universal plasma" or "universal platelets", meaning not grouped any more, compatible with any recipient whichever is the group of the donor. The same molecule allows organ transplants between donor and recipient of a different blood group. Last: now plasma derivative drug (IgM based) are becoming a reality.